AnaptysBio Financials

ANAB Stock  USD 24.10  1.83  8.22%   
Based on the analysis of AnaptysBio's profitability, liquidity, and operating efficiency, AnaptysBio may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, AnaptysBio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 19.2 M, whereas Total Assets are forecasted to decline to about 354.3 M. Key indicators impacting AnaptysBio's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.01920.0202
Notably Down
Slightly volatile
Current Ratio11.1710.8657
Fairly Up
Slightly volatile
Investors should never underestimate AnaptysBio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor AnaptysBio's cash flow, debt, and profitability to make informed and accurate decisions about investing in AnaptysBio.

Net Income

(155.44 Million)

  
Understanding current and past AnaptysBio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AnaptysBio's financial statements are interrelated, with each one affecting the others. For example, an increase in AnaptysBio's assets may result in an increase in income on the income statement.
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.

AnaptysBio Stock Summary

AnaptysBio competes with Crinetics Pharmaceuticals, Rhythm Pharmaceuticals, Kura Oncology, and CytomX Therapeutics. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS0327241065
CUSIP032724106
LocationCalifornia; U.S.A
Business Address10770 Wateridge Circle,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.anaptysbio.com
Phone858 362 6295
CurrencyUSD - US Dollar

AnaptysBio Key Financial Ratios

AnaptysBio Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets435.2M416.6M643.1M610.4M452.4M354.3M
Other Current Liab871K15.3M11.3M20.0M29.2M30.6M
Net Debt(168.8M)(250.1M)(474.8M)(51.9M)(18.2M)(19.1M)
Retained Earnings(244.0M)(264.0M)(321.8M)(450.5M)(614.1M)(583.4M)
Accounts Payable16.2M4.2M1.7M2.8M4.7M4.2M
Cash171.0M250.5M495.7M71.3M36.0M34.2M
Other Current Assets3.5M5.8M4.9M4.5M9.1M9.5M
Total Liab30.2M19.8M286.6M348.3M364.3M382.5M
Total Current Assets377.7M396.6M553.9M447.2M406.8M300.8M
Short Term Debt2.2M342K3.0M3.3M3.6M2.8M
Other Liab796K654K251.1M304.4M350.1M367.6M
Net Tangible Assets405.0M396.7M627.0M584.3M672.0M705.6M
Other Assets208K139K18.2M256K294.4K279.7K
Capital Surpluse648.7M660.7M678.6M717.8M825.5M517.6M
Net Invested Capital406.4M396.7M356.4M262.1M88.1M83.7M

AnaptysBio Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense1.0M4.0M1.5M21.1M18.1M19.0M
Total Revenue8M75M63.2M10.3M17.2M24.4M
Gross Profit(91.3M)(5.0M)(35.3M)8.0M14.8M15.5M
Operating Income(107.4M)(23.9M)(56.8M)(115.2M)(164.4M)(156.2M)
Ebit(107.4M)(19.9M)(57.8M)(107.6M)(145.5M)(138.3M)
Research Development99.3M80.0M98.5M88.8M132.3M138.9M
Ebitda(96.4M)(19.4M)(55.7M)(105.3M)(143.2M)(136.0M)
Income Before Tax(97.5M)(19.9M)(57.8M)(128.7M)(163.6M)(155.4M)
Net Income(97.3M)(19.9M)(57.2M)(128.7M)(163.6M)(155.4M)
Income Tax Expense(152K)(11K)(603K)24K(4K)(3.8K)
Cost Of Revenue99.3M80.0M98.5M2.3M2.4M2.3M
Interest Income11.0M4.0M431K7.6M17.8M18.7M
Net Interest Income9.9M4.0M(1.0M)(13.6M)456K420.4K

AnaptysBio Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash57.4M79.4M245.2M(424.4M)(35.3M)(33.6M)
Free Cash Flow(70.3M)(14.7M)(47.3M)(74.0M)(121.6M)(115.5M)
Depreciation514K559K2.1M2.3M2.4M2.5M
Other Non Cash Items676K487K1.5M18.6M7.6M7.9M
Capital Expenditures805K569K1.4M358K807K572.8K
Net Income(97.3M)(19.9M)(57.8M)(128.7M)(163.6M)(155.4M)
End Period Cash Flow171.1M250.5M495.7M71.3M36.0M34.2M
Investments132.2M95.0M40.2M(394.5M)117.1M122.9M
Change To Netincome676K12.0M1.9M18.6M21.4M22.5M

AnaptysBio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining AnaptysBio's current stock value. Our valuation model uses many indicators to compare AnaptysBio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AnaptysBio competition to find correlations between indicators driving AnaptysBio's intrinsic value. More Info.
AnaptysBio is rated fifth in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, AnaptysBio's Return On Equity is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AnaptysBio's earnings, one of the primary drivers of an investment's value.

AnaptysBio Systematic Risk

AnaptysBio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AnaptysBio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on AnaptysBio correlated with the market. If Beta is less than 0 AnaptysBio generally moves in the opposite direction as compared to the market. If AnaptysBio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AnaptysBio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AnaptysBio is generally in the same direction as the market. If Beta > 1 AnaptysBio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in AnaptysBio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AnaptysBio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AnaptysBio growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.11)

At present, AnaptysBio's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

AnaptysBio November 25, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of AnaptysBio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AnaptysBio. We use our internally-developed statistical techniques to arrive at the intrinsic value of AnaptysBio based on widely used predictive technical indicators. In general, we focus on analyzing AnaptysBio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AnaptysBio's daily price indicators and compare them against related drivers.

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stocks Directory
Find actively traded stocks across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
CEOs Directory
Screen CEOs from public companies around the world
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities